Kfoury Charlotte
Mcgill J Med. 2007 Jul;10(2):112-20.
Advances in biotechnology necessitate both an understanding of scientific principles and ethical implications to be clinically applicable in medicine. In this regard, therapeutic cloning offers significant potential in regenerative medicine by circumventing immunorejection, and in the cure of genetic disorders when used in conjunction with gene therapy. Therapeutic cloning in the context of cell replacement therapy holds a huge potential for de novo organogenesis and the permanent treatment of Parkinson's disease, Duchenne muscular dystrophy, and diabetes mellitus as shown by in vivo studies. Scientific roadblocks impeding advancement in therapeutic cloning are tumorigenicity, epigenetic reprogramming, mitochondrial heteroplasmy, interspecies pathogen transfer, low oocyte availability. Therapeutic cloning is also often tied to ethical considerations concerning the source, destruction and moral status of IVF embryos based on the argument of potential. Legislative and funding issues are also addressed. Future considerations would include a distinction between therapeutic and reproductive cloning in legislative formulations.
生物技术的进步要求人们既要理解科学原理,又要明白伦理影响,以便在医学临床中得以应用。在这方面,治疗性克隆通过规避免疫排斥,以及与基因治疗联合使用时在治愈遗传疾病方面,在再生医学中具有巨大潜力。如体内研究所示,在细胞替代疗法背景下的治疗性克隆在器官再生以及帕金森病、杜氏肌营养不良症和糖尿病的永久治疗方面具有巨大潜力。阻碍治疗性克隆进展的科学障碍包括致瘤性、表观遗传重编程、线粒体异质性、种间病原体转移、卵母细胞可用性低。治疗性克隆还常常与基于潜在性论点的有关体外受精胚胎来源、破坏及道德地位的伦理考量联系在一起。文中还讨论了立法和资金问题。未来的考量将包括在立法制定中区分治疗性克隆和生殖性克隆。